News & Articles

Explore ways to improve time to result in critical pathways such as sepsis

In a 17-4 vote, the FDA vaccine advisory committee recommended that Pfizer/BioNTech’s COVID-19 vaccine should be distributed to the U.S.

Watch this on-demand webinar to learn how COVID immune responses can be assessed using a novel microfluidic in-solution immunoassay platform

Access SARS-CoV-2 IgG II test is a semi-quantitative assay that measures patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection

Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens

Two different dosing regimens demonstrated efficacy with one showing a better profile

The collaboration aims to secure manufacturing and testing capacity in the next phase of the pandemic

As SARS-CoV-2 vaccines become available, Siemens Healthineers is ready with fully automated antibody tests that can be used to help inform whether broad vaccination programs are working

Test adds to QIAGEN’s growing portfolio of PCR testing solutions for COVID-19 testing

Join scientists from across the globe to explore the latest developments in biopharma, from new research techniques to cutting-edge technologies and resources to advance your work

QIAreach SARS-CoV-2 Antigen Test is an important step towards decentralized mass screening by processing samples in 2–15 minutes

Phase 3 part of clinical trial to enrol over 30,000 volunteers worldwide

Exclusive interviews, free downloads, the latest methods and much more to help support your immuno-oncology research

The kit promises to be a low cost, high-sensitivity diagnostic test for COVID-19 detection

The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 100% sensitivity at >18 days post symptom onset and post positive PCR

Underscores importance of serological testing using the S1 subunit for worldwide seroprevalence and vaccine development

Discover the importance of high-throughput and robust methodologies for finding ‘needle-in-the-haystack’ therapeutic antibodies

Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected

Party during Neuroscience 2018 celebrates the importance of effective conversation between scientists and manufacturers

Discover how AFABILITY founder Dr. Alison Gray is enabling the transition from animal-derived to non-animal-derived antibodies